Thomas v. C R Bard Incorporated

District Court, S.D. New York·Decided November 7, 2022·No. 7:20-cv-02738-CS·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------x WILLIAM T. THOMAS,

Plaintiff, OPINION & ORDER - against - No. 20-CV-2738 (CS) C.R. BARD, INC. a foreign corporation, and BARD PERIPHERAL VASCULAR, INC.,

Defendants. -------------------------------------------------------------x

Appearances:

Philip M. Busman Nelson Mullins Riley & Scarborough LLC Washington, D.C.

Elizabeth A. Falconer Nelson Mullins Riley & Scarborough LLC Atlanta, GA

Toby S. Soli Greenberg Traurig, LLP New York, N.Y. Counsel for Defendants

Seibel, J. Before the Court is the motion for summary judgment of Defendants C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (collectively, “Bard”). (ECF No. 44.) For the following reasons, Defendants’ motion is GRANTED. I. BACKGROUND The following facts are based on Defendants’ Local Civil Rule 56.1 Statement, (ECF No. 47 (“Ds’ 56.1 Stmt.”)), and supporting materials, and are undisputed except as noted.1 Facts

Plaintiff William T. Thomas suffered from left lower extremity deep vein thrombosis (“DVT”) and pulmonary emboli (“PE”). (ECF No. 46-1 at 4; Fact Sheet at 6.) On July 17, 2014, non-party Dr. Andrei Frost implanted a Denali® Filter (the “Filter”), manufactured by Bard, in Plaintiff’s inferior vena cava (“IVC”), which is the largest vein in the body. (Ds’ 56.1 Stmt. ¶¶ 1, 15.) The Filter is a prescription device and has been cleared by the FDA through the 510(k) process detailed in the Food, Drug, and Cosmetic Act. (Id. ¶ 14; ECF No. 46-5 at 2-4.) It has a conical shape, with two tiers of struts consisting of six “arms” and six “legs.” (Ds’ 56.1 Stmt. ¶ 15; ECF No. 46-6 at 1.) Once implanted into the IVC, the arms and legs open and anchor the Filter to the IVC’s walls. (Ds’ 56.1 Stmt. ¶ 15; ECF No. 46-6 at 1.) The Filter prevents blood

1 Plaintiff did not file a responsive Rule 56.1 Statement or any papers in opposition to this motion. Local Civil Rule 56.1 requires that the party opposing a motion for summary judgment submit a counterstatement responding to the moving party’s statement of material facts, indicating which facts are admitted and which the opposing party contends are in dispute and require a trial. L.R. 56.1(b). Under the Local Rule, “[i]f the opposing party . . . fails to controvert a fact so set forth in the moving party’s Rule 56.1 statement, that fact will be deemed admitted.” Giannullo v. City of N.Y., 322 F.3d 139, 140 (2d Cir. 2003) (citing L.R. 56.1(c)). Pro se litigants are not excused from this requirement. SEC v. Tecumseh Holdings Corp., 765 F. Supp. 2d 340, 344 n.4 (S.D.N.Y. 2011). As Defendants served Plaintiff with the requisite notice pursuant to Local Civil Rule 56.2, (see ECF No. 45), I have discretion to consider any properly supported facts in Defendants’ Local Civil Rule 56.1 Statement admitted. But granting Plaintiff solicitude, I have considered the excerpts of Plaintiff’s deposition testimony provided by Defendants, (ECF No. 46-3 (“P’s Depo. 1”); ECF No. 46-4 (“P’s Depo. 2”)), statements in his Complaint, (ECF No. 1 (“Comp.”)), and his Fact Sheet, (ECF No. 46-2 (“Fact Sheet”)). See Holtz v. Rockefeller & Co., 258 F.3d 62, 73 (2d Cir. 2001) (“[W]hile a court is not required to consider what the parties fail to point out in their Local Rule 56.1 statements, it may in its discretion opt to conduct an assiduous review of the record even where one of the parties has failed to file such a statement.”) (cleaned up). clots in the “deep veins of the body” from traveling to the heart or lungs, thereby stopping a possible PE, which can lead to chest pain, shortness of breath, and death. (Ds’ 56.1 Stmt. ¶ 15; ECF No. 46-6 at 1.) IVC filters, like the one implanted here, are often used in patients who have DVT or blood clots to reduce the risk of PE. (Ds’ 56.1 Stmt. ¶ 16.) The Filter is not sold

directly to patients. (Id. ¶ 17.) Plaintiff alleges that since the Filter was implanted, he has spit up blood, felt depressed, and been “scared to go to the hospital.” (Fact Sheet at 14.) Plaintiff testified that “[a]s soon as they did the congestive heart failure procedure, and they put the filter in, that’s when everything started happening to me. I start[ed] throwing up blood every day. I was coughing more. My stomach was hurting a lot” and “I was vomiting a lot of blood, and when I was getting up I was getting a sharp pain in my abdomen.” (P’s Depo. 1 at 51:12-25, 60:15-21.) Plaintiff also alleges that he can now no longer participate in martial arts and dancing due to alleged complications from the implantation. (Fact Sheet at 20.) Plaintiff also suffers from gout, which causes pain and makes it harder to move around, walk, dance, and do martial arts. (P’s Depo. 1 at 28:10-

Free access — add to your briefcase to read the full text and ask questions with AI

Thomas v. C R Bard Incorporated, (S.D.N.Y. 2022).

Thomas v. C R Bard Incorporated (Thomas v. C R Bard Incorporated) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Hendrix Ex Rel. Gp v. Evenflo Co., Inc.
609 F.3d 1183 (Eleventh Circuit, 2010)
Douglas C. Kilpatrick v. Breg, Inc.
613 F.3d 1329 (Eleventh Circuit, 2010)
Ronwin v. Bayer Corporation
332 F. App'x 508 (Tenth Circuit, 2009)
Tracy v. Freshwater
623 F.3d 90 (Second Circuit, 2010)
Hughes v. Stryker Sales Corp.
423 F. App'x 878 (Eleventh Circuit, 2011)
Fernandez-Pineiro v. Bausch & Lomb, Inc.
429 F. App'x 249 (Fourth Circuit, 2011)
Fujitsu Limited v. Federal Express Corporation
247 F.3d 423 (Second Circuit, 2001)
Laura Holtz v. Rockefeller & Co., Inc.
258 F.3d 62 (Second Circuit, 2001)
Mark Giannullo v. City of New York
322 F.3d 139 (Second Circuit, 2003)
Wills v. Amerada Hess Corp.
379 F.3d 32 (Second Circuit, 2004)
Holcomb v. Iona College
521 F.3d 130 (Second Circuit, 2008)
Krasnopolsky v. Warner-Lambert Co.
799 F. Supp. 1342 (E.D. New York, 1992)
In Re Viagra Products Liability Litigation
658 F. Supp. 2d 950 (D. Minnesota, 2009)
In Re Baycol Products Litigation
321 F. Supp. 2d 1118 (D. Minnesota, 2004)